What is Profusa?
Profusa is a pioneering medical technology firm specializing in the development of tissue-integrating biosensors designed for the continuous, real-time monitoring of body chemistries. Its flagship innovation, the Lumee Oxygen Platform, has achieved a CE Mark for use within the European Union, marking a critical milestone in the company's commercialization strategy. By providing healthcare providers and researchers with precise, longitudinal data on tissue oxygen levels, Profusa addresses a significant gap in clinical management. The company operates at the intersection of biotechnology and digital health, positioning itself as a key player in the evolution of personalized medicine and remote diagnostic solutions.
How much funding has Profusa raised?
Profusa has raised a total of $185M across 10 funding rounds:
Private Equity
$2.8M
Series A
$2.8M
Private Equity
$11.3M
Series B
$13.2M
Grant
$7.5M
Series C
$45M
Debt
$1M
Stock/Share Issuance
$100M
Debt
$350K
Private Equity (2013): $2.8M, investors not publicly disclosed
Series A (2013): $2.8M, investors not publicly disclosed
Private Equity (2015): $11.3M, investors not publicly disclosed
Series B (2015): $13.2M backed by Asset Management Ventures and Qihoo 360
Grant (2016): $7.5M with participation from Defense Advanced Research Projects Agency
Series C (2018): $45M led by VMS Asset Management, Maxim Integrated Ventures, 3E Bioventures Capital, Atinum Investment, and Tasly Holding Group
Debt (2020): $1M supported by PPP
Stock/Share Issuance (2025): $100M featuring Ascent Partners
Debt (2026): $350K backed by Ascent Partners
Key Investors in Profusa
VMS Asset Management
A Hong Kong-based private equity firm providing venture capital, securities-brokerage, and corporate-advisory services since 2006.
3E Bioventures Capital
A science-driven investment firm with offices in Beijing, Shanghai, and the San Francisco Bay Area, focusing on unmet medical needs.
Asset Management Ventures
A long-standing investment firm that has evolved into a family office, focusing on technology-based opportunities and visionary entrepreneurship.
What's next for Profusa?
With the support of its latest strategic financing, Profusa is well-positioned to accelerate the global deployment of its sensing platforms. The company's roadmap likely involves expanding its regulatory footprint and deepening its integration into existing healthcare infrastructure. By leveraging its established partnerships and technological expertise, Profusa aims to transition from a research-heavy development phase into a broader commercial scale-up, focusing on enhancing clinical outcomes through continuous, non-invasive biochemical monitoring. The firm remains focused on scaling its manufacturing and distribution capabilities to meet the growing demand for innovative, data-driven patient management tools.
See full Profusa company page
